177 Lu PSMA 617 - RadioMedix

Drug Profile

177 Lu PSMA 617 - RadioMedix

Alternative Names: 177 Lu PSMA-617

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator RadioMedix
  • Developer Excel Diagnostics and Nuclear Oncology Center; RadioMedix; University of California at Los Angeles
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 10 Feb 2017 Radiomedix plans a phase II trial for Prostate cancer (Metastatic disease) in USA (NCT03042312)
  • 07 Feb 2017 Preclinical trial in Prostate cancer (Metastatic disease) in USA (Parenteral)
  • 07 Feb 2017 USFDA approves IND application for 177 Lu PSMA-617 in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top